Capricor Therapeutics (NASDAQ:CAPR) Price Target Increased to $25.00 by Analysts at Maxim Group

Capricor Therapeutics (NASDAQ:CAPR) had its price objective upped by Maxim Group from $12.00 to $25.00 in a report issued on Wednesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

CAPR has been the subject of several other research reports. Oppenheimer restated an outperform rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald reissued an overweight rating and issued a $8.00 target price on shares of Capricor Therapeutics in a report on Friday, September 20th. Finally, HC Wainwright reiterated a buy rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat.com, Capricor Therapeutics has an average rating of Moderate Buy and an average target price of $22.60.

Capricor Therapeutics Price Performance

CAPR stock opened at $9.95 on Wednesday. The business’s 50-day moving average is $4.80 and its two-hundred day moving average is $5.31. The firm has a market capitalization of $318.19 million, a P/E ratio of -11.44 and a beta of 3.92. Capricor Therapeutics has a 1 year low of $2.68 and a 1 year high of $12.87.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. On average, analysts expect that Capricor Therapeutics will post -1.14 EPS for the current year.

Insider Buying and Selling

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the stock in a transaction on Friday, September 20th. The shares were bought at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CAPR. BNP Paribas Financial Markets purchased a new position in Capricor Therapeutics during the 1st quarter valued at about $40,000. Main Street Financial Solutions LLC raised its stake in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Capricor Therapeutics during the second quarter worth about $147,000. Finally, Renaissance Technologies LLC raised its position in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.